DOI QR코드

DOI QR Code

Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents

  • Son, Jang-Won (Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Ung (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) ;
  • Park, Jong-Seon (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) ;
  • Kim, Young-Jo (Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center) ;
  • Jang, Jae-Sik (Division of Cardiology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Yang, Tae-Hyun (Division of Cardiology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Kim, Dong-Soo (Division of Cardiology, Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Kim, Dong-Kie (Division of Cardiology, Department of Internal Medicine, Inje University Haeundae Paik Hospital) ;
  • Seol, Sang-Hoon (Division of Cardiology, Department of Internal Medicine, Inje University Haeundae Paik Hospital) ;
  • Kim, Doo-Il (Division of Cardiology, Department of Internal Medicine, Inje University Haeundae Paik Hospital) ;
  • Nam, Chang-Wook (Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Hur, Seung-Ho (Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center) ;
  • Kim, Kwon-Bae (Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Medical Center)
  • Published : 2013.01.01

Abstract

Background/Aims: The Taxus Liberte stent (Boston Scientific Co.) evolved from the Taxus Express stent, with enhanced stent deliverability and uniform drug delivery. This study was designed to compare angiographic and clinical outcomes in real-world practice between the Taxus Liberte and Taxus Express stents. Methods: Between 2006 and 2008, 240 patients receiving the Taxus Liberte stent at three centers were registered and compared to historical control patients who had received the Taxus Express stent (n = 272). After propensity score matching, 173 patients treated with the Taxus Liberte stent and the same number of patients treated with the Taxus Express stent were selected. The primary outcome was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), ischemia driven target vessel revascularization (TVR), and stent thrombosis (ST) at 1 year. An additional angiographic assessment was conducted at 9 to 12 months. Results: The study showed no significant difference between the Taxus Express and Taxus Liberte stents (death, 1.73% vs. 2.31%, p = 1.000; MI, 0% vs. 1.73%, p = 0.2478; TVR, 2.31% vs. 1.16%, p = 0.6848; and ST, 0% vs. 1.16%, p = 0.4986). The total MACE rate at 1 year did not differ between the groups (4.05% in Taxus Express vs. 4.05% in Taxus Liberte, p = 1.000). In addition, the binary restenosis rate did not differ (2.25% in Taxus Express vs. 1.80% in Taxus Liberte, p = 0.6848). Conclusions: In real-world experience with the two Taxus stent designs, both stents showed similarly good clinical and angiographic outcomes at 1 year. A long-term follow-up study is warranted.

Keywords

References

  1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780. https://doi.org/10.1056/NEJMoa012843
  2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323. https://doi.org/10.1056/NEJMoa035071
  3. Schofer J, Schluter M, Gershlick AH, et al. Sirolimuseluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: doubleblind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099. https://doi.org/10.1016/S0140-6736(03)14462-5
  4. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderaterelease polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794. https://doi.org/10.1161/01.CIR.0000086926.62288.A6
  5. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231. https://doi.org/10.1056/NEJMoa032441
  6. Turco MA, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberte stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv 2008;1:699-709. https://doi.org/10.1016/j.jcin.2008.09.007
  7. Kim U, Seol SH, Kim DI, et al. Clinical outcomes and the risk factors of coronary artery aneurysms that developed after drug-eluting stent implantation. Circ J 2011;75:861-867. https://doi.org/10.1253/circj.CJ-10-0635
  8. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-2351. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  9. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 1998;17:2265-2281. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
  10. Halkin A, Stone GW. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 2004;17:271-282. https://doi.org/10.1111/j.1540-8183.2004.04040.x
  11. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxeleluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113. https://doi.org/10.1056/NEJMoa062598
  12. Kitahara H, Kobayashi Y, Yamaguchi M, et al. Damage to polymer of paclitaxel-eluting stent. Circ J 2008;72:1907-1908. https://doi.org/10.1253/circj.CJ-08-0024
  13. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: sixand twelve-month results from a randomized, doubleblind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42. https://doi.org/10.1161/01.CIR.0000047700.58683.A1
  14. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxeleluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947. https://doi.org/10.1161/01.CIR.0000127110.49192.72
  15. Schwalm JD, Ahmad M, Velianou JL, Pericak D, Natarajan MK. Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience. Can J Cardiol 2010;26:e40-e44. https://doi.org/10.1016/S0828-282X(10)70005-2
  16. Rogers CD. Optimal stent design for drug delivery. Rev Cardiovasc Med 2004;5 Suppl 2:S9-S15. https://doi.org/10.1016/j.carrad.2004.04.002
  17. Briguori C, Sarais C, Pagnotta P, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 2002;40:403-409. https://doi.org/10.1016/S0735-1097(02)01989-7
  18. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-2821. https://doi.org/10.1161/01.CIR.103.23.2816
  19. Turco MA, Ormiston JA, Popma JJ, et al. Polymerbased, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007;49:1676-1683. https://doi.org/10.1016/j.jacc.2007.01.069
  20. Hausleiter J, Kastrati A, Mehilli J, et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. Am Heart J 2003;146:882-886. https://doi.org/10.1016/S0002-8703(03)00435-6

Cited by

  1. Stents: Biomechanics, Biomaterials, and Insights from Computational Modeling vol.45, pp.4, 2013, https://doi.org/10.1007/s10439-017-1806-8